STOCK TITAN

[8-K] Labcorp Holdings Inc. Reports Material Event

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Labcorp (NYSE: LH) entered into a $1.0 billion senior unsecured revolving credit facility that replaces its 2021 agreement and pushes final maturity from April 2026 to June 27 2030. The Fourth Amended and Restated Credit Agreement, led by Bank of America, also adds a $500 million accordion, a $100 million swingline, and a $150 million L/C sub-limit.

Pricing is floating: (i) SOFR + 0.805%–1.300% or (ii) base rate + 0–0.300%, plus a facility fee of 0.070%–0.200%, all tiered to long-term debt ratings. Key covenant requires a net leverage ratio ≤ 4.0×, expandable to 4.5× for four quarters following material acquisitions (unlimited leverage-holiday elections subject to reset conditions). As of closing, no amounts are drawn. The agreement contains customary reps, covenants, and default provisions.

Labcorp (NYSE: LH) ha stipulato una linea di credito revolving senior unsecured da 1,0 miliardi di dollari che sostituisce l'accordo del 2021 e posticipa la scadenza finale da aprile 2026 al 27 giugno 2030. Il Quarto Accordo di Credito Emendato e Ristabilito, guidato da Bank of America, include anche una opzione di aumento (accordion) da 500 milioni di dollari, una linea swingline da 100 milioni di dollari e un sottolimite per lettere di credito (L/C) da 150 milioni di dollari.

Il prezzo è variabile: (i) SOFR + 0,805%–1,300% oppure (ii) tasso base + 0–0,300%, più una commissione sulla linea dello 0,070%–0,200%, tutte basate sulla valutazione del debito a lungo termine. Il covenant principale richiede un rapporto di leva finanziaria netta ≤ 4,0×, estendibile a 4,5× per quattro trimestri dopo acquisizioni significative (con possibilità illimitata di sospensione della leva, soggetta a condizioni di reset). Alla chiusura, non sono stati effettuati prelievi. L'accordo include le consuete dichiarazioni, covenant e clausole di default.

Labcorp (NYSE: LH) ha firmado una línea de crédito revolvente senior sin garantía por 1.000 millones de dólares que reemplaza su acuerdo de 2021 y extiende la fecha de vencimiento final de abril de 2026 al 27 de junio de 2030. El Cuarto Acuerdo de Crédito Enmendado y Restablecido, liderado por Bank of America, también añade un acordeón de 500 millones de dólares, una línea swingline de 100 millones de dólares y un sub-límite para cartas de crédito (L/C) de 150 millones de dólares.

El precio es variable: (i) SOFR + 0,805%–1,300% o (ii) tasa base + 0–0,300%, más una comisión de la facilidad del 0,070%–0,200%, todo escalonado según las calificaciones de deuda a largo plazo. El convenio clave requiere una relación de apalancamiento neto ≤ 4,0×, ampliable a 4,5× durante cuatro trimestres tras adquisiciones importantes (elecciones de vacaciones ilimitadas de apalancamiento sujetas a condiciones de reinicio). Al cierre, no se han realizado retiros. El acuerdo contiene representaciones, convenios y disposiciones de incumplimiento habituales.

Labcorp (NYSE: LH)는 2021년 계약을 대체하는 10억 달러 규모의 선순위 무담보 회전 신용 시설을 체결했으며, 최종 만기를 2026년 4월에서 2030년 6월 27일로 연장했습니다. 뱅크오브아메리카가 주도하는 네 번째 수정 및 재작성된 신용 계약에는 5억 달러의 확장 옵션(accordion), 1억 달러의 스윙라인, 그리고 1억 5천만 달러의 신용장(L/C) 하위 한도가 추가되었습니다.

금리는 변동형으로, (i) SOFR + 0.805%–1.300% 또는 (ii) 기준 금리 + 0–0.300%이며, 장기 부채 등급에 따라 0.070%–0.200%의 시설 수수료가 부과됩니다. 주요 계약 조건으로는 순 레버리지 비율 ≤ 4.0배가 요구되며, 중대한 인수 후 4분기 동안 4.5배까지 확장 가능합니다(무제한 레버리지 휴가 선택은 재설정 조건에 따름). 계약 체결 시점에 차입금은 전혀 없는 상태입니다. 계약에는 일반적인 진술, 계약 조건, 그리고 기본 조항이 포함되어 있습니다.

Labcorp (NYSE: LH) a conclu une facilité de crédit renouvelable senior non garantie de 1,0 milliard de dollars qui remplace son accord de 2021 et repousse l'échéance finale d'avril 2026 au 27 juin 2030. Le quatrième accord de crédit amendé et rétabli, dirigé par Bank of America, ajoute également un accordéon de 500 millions de dollars, une ligne swingline de 100 millions de dollars et un sous-limite de lettres de crédit (L/C) de 150 millions de dollars.

La tarification est variable : (i) SOFR + 0,805 %–1,300 % ou (ii) taux de base + 0–0,300 %, plus une commission de facilité de 0,070 %–0,200 %, le tout échelonné selon les notations de dette à long terme. La clause clé exige un ratio d'endettement net ≤ 4,0×, extensible à 4,5× pendant quatre trimestres après des acquisitions majeures (choix de suspension de levier illimités soumis à des conditions de réinitialisation). À la clôture, aucun montant n'a été tiré. L'accord contient les déclarations, engagements et clauses de défaut habituels.

Labcorp (NYSE: LH) hat eine unbesicherte revolvierende Senior-Kreditlinie über 1,0 Milliarden US-Dollar abgeschlossen, die die Vereinbarung von 2021 ersetzt und die Endfälligkeit von April 2026 auf den 27. Juni 2030 verschiebt. Das vierte geänderte und neu gefasste Kreditabkommen, angeführt von der Bank of America, beinhaltet zudem eine 500-Millionen-Dollar-Accordion-Option, eine 100-Millionen-Dollar-Swingline und ein 150-Millionen-Dollar-L/C-Unterlimit.

Die Preisgestaltung ist variabel: (i) SOFR + 0,805 %–1,300 % oder (ii) Basiszinssatz + 0–0,300 %, zuzüglich einer Gebühr für die Kreditlinie von 0,070 %–0,200 %, alles gestaffelt nach langfristigen Kreditratings. Die wichtigste Auflage verlangt eine Netto-Verschuldungsquote ≤ 4,0×, erweiterbar auf 4,5× für vier Quartale nach wesentlichen Akquisitionen (unbegrenzte Leverage-Urlaubswahl vorbehaltlich Rücksetzbedingungen). Zum Abschlusszeitpunkt sind keine Beträge abgerufen. Das Abkommen enthält übliche Zusicherungen, Auflagen und Kündigungsbestimmungen.

Positive
  • Extension of the company’s $1 billion revolving credit facility maturity from 2026 to 2030, enhancing long-term liquidity certainty
  • Addition of a $500 million upsizing option increases financial flexibility for acquisitions or other strategic uses
Negative
  • None.

Insights

TL;DR: New $1B revolver, 2030 maturity, added $500M accordion—boosts liquidity and strategic flexibility.

Extending the revolver by four years materially de-risks near-term refinancing and provides ample dry powder for bolt-on M&A. Zero initial borrowings mean immediate leverage is unchanged, yet the leverage covenant (4.0×, with 4.5× holiday) preserves headroom given Labcorp’s historical sub-3× profile. Pricing corridors are tight and rating-linked, reflecting solid credit quality. Overall, investors gain visibility on liquidity through 2030 at competitive costs.

TL;DR: Standard terms; covenant discipline remains, limited credit impact until facility is drawn.

From a credit perspective the package is neutral. The unsecured structure, unchanged size, and leverage guardrails mirror prevailing market norms. The accordion could raise gross debt by 50%, but only if growth opportunities arise; covenant headroom and leverage holidays mitigate event risk. Absent borrowings, metrics and ratings stay intact, so spreads should remain stable.

Labcorp (NYSE: LH) ha stipulato una linea di credito revolving senior unsecured da 1,0 miliardi di dollari che sostituisce l'accordo del 2021 e posticipa la scadenza finale da aprile 2026 al 27 giugno 2030. Il Quarto Accordo di Credito Emendato e Ristabilito, guidato da Bank of America, include anche una opzione di aumento (accordion) da 500 milioni di dollari, una linea swingline da 100 milioni di dollari e un sottolimite per lettere di credito (L/C) da 150 milioni di dollari.

Il prezzo è variabile: (i) SOFR + 0,805%–1,300% oppure (ii) tasso base + 0–0,300%, più una commissione sulla linea dello 0,070%–0,200%, tutte basate sulla valutazione del debito a lungo termine. Il covenant principale richiede un rapporto di leva finanziaria netta ≤ 4,0×, estendibile a 4,5× per quattro trimestri dopo acquisizioni significative (con possibilità illimitata di sospensione della leva, soggetta a condizioni di reset). Alla chiusura, non sono stati effettuati prelievi. L'accordo include le consuete dichiarazioni, covenant e clausole di default.

Labcorp (NYSE: LH) ha firmado una línea de crédito revolvente senior sin garantía por 1.000 millones de dólares que reemplaza su acuerdo de 2021 y extiende la fecha de vencimiento final de abril de 2026 al 27 de junio de 2030. El Cuarto Acuerdo de Crédito Enmendado y Restablecido, liderado por Bank of America, también añade un acordeón de 500 millones de dólares, una línea swingline de 100 millones de dólares y un sub-límite para cartas de crédito (L/C) de 150 millones de dólares.

El precio es variable: (i) SOFR + 0,805%–1,300% o (ii) tasa base + 0–0,300%, más una comisión de la facilidad del 0,070%–0,200%, todo escalonado según las calificaciones de deuda a largo plazo. El convenio clave requiere una relación de apalancamiento neto ≤ 4,0×, ampliable a 4,5× durante cuatro trimestres tras adquisiciones importantes (elecciones de vacaciones ilimitadas de apalancamiento sujetas a condiciones de reinicio). Al cierre, no se han realizado retiros. El acuerdo contiene representaciones, convenios y disposiciones de incumplimiento habituales.

Labcorp (NYSE: LH)는 2021년 계약을 대체하는 10억 달러 규모의 선순위 무담보 회전 신용 시설을 체결했으며, 최종 만기를 2026년 4월에서 2030년 6월 27일로 연장했습니다. 뱅크오브아메리카가 주도하는 네 번째 수정 및 재작성된 신용 계약에는 5억 달러의 확장 옵션(accordion), 1억 달러의 스윙라인, 그리고 1억 5천만 달러의 신용장(L/C) 하위 한도가 추가되었습니다.

금리는 변동형으로, (i) SOFR + 0.805%–1.300% 또는 (ii) 기준 금리 + 0–0.300%이며, 장기 부채 등급에 따라 0.070%–0.200%의 시설 수수료가 부과됩니다. 주요 계약 조건으로는 순 레버리지 비율 ≤ 4.0배가 요구되며, 중대한 인수 후 4분기 동안 4.5배까지 확장 가능합니다(무제한 레버리지 휴가 선택은 재설정 조건에 따름). 계약 체결 시점에 차입금은 전혀 없는 상태입니다. 계약에는 일반적인 진술, 계약 조건, 그리고 기본 조항이 포함되어 있습니다.

Labcorp (NYSE: LH) a conclu une facilité de crédit renouvelable senior non garantie de 1,0 milliard de dollars qui remplace son accord de 2021 et repousse l'échéance finale d'avril 2026 au 27 juin 2030. Le quatrième accord de crédit amendé et rétabli, dirigé par Bank of America, ajoute également un accordéon de 500 millions de dollars, une ligne swingline de 100 millions de dollars et un sous-limite de lettres de crédit (L/C) de 150 millions de dollars.

La tarification est variable : (i) SOFR + 0,805 %–1,300 % ou (ii) taux de base + 0–0,300 %, plus une commission de facilité de 0,070 %–0,200 %, le tout échelonné selon les notations de dette à long terme. La clause clé exige un ratio d'endettement net ≤ 4,0×, extensible à 4,5× pendant quatre trimestres après des acquisitions majeures (choix de suspension de levier illimités soumis à des conditions de réinitialisation). À la clôture, aucun montant n'a été tiré. L'accord contient les déclarations, engagements et clauses de défaut habituels.

Labcorp (NYSE: LH) hat eine unbesicherte revolvierende Senior-Kreditlinie über 1,0 Milliarden US-Dollar abgeschlossen, die die Vereinbarung von 2021 ersetzt und die Endfälligkeit von April 2026 auf den 27. Juni 2030 verschiebt. Das vierte geänderte und neu gefasste Kreditabkommen, angeführt von der Bank of America, beinhaltet zudem eine 500-Millionen-Dollar-Accordion-Option, eine 100-Millionen-Dollar-Swingline und ein 150-Millionen-Dollar-L/C-Unterlimit.

Die Preisgestaltung ist variabel: (i) SOFR + 0,805 %–1,300 % oder (ii) Basiszinssatz + 0–0,300 %, zuzüglich einer Gebühr für die Kreditlinie von 0,070 %–0,200 %, alles gestaffelt nach langfristigen Kreditratings. Die wichtigste Auflage verlangt eine Netto-Verschuldungsquote ≤ 4,0×, erweiterbar auf 4,5× für vier Quartale nach wesentlichen Akquisitionen (unbegrenzte Leverage-Urlaubswahl vorbehaltlich Rücksetzbedingungen). Zum Abschlusszeitpunkt sind keine Beträge abgerufen. Das Abkommen enthält übliche Zusicherungen, Auflagen und Kündigungsbestimmungen.

false 0000920148 0000920148 2025-06-27 2025-06-27
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

June 27, 2025

(Date of earliest event reported)

 

 

LABCORP HOLDINGS INC.

(Exact name of Registrant as Specified in its Charter)

 

 

 

Delaware   1-11353   99-2588107
(State or other jurisdiction
of Incorporation)
 

(Commission

File Number)

  (I.R.S. Employer
Identification No.)

 

358 South Main Street  
Burlington,   North Carolina   27215
(Address of principal executive offices)   (Zip Code)

(Registrant’s telephone number, including area code) (336) 229-1127

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading
Symbol(s)

 

Name of each exchange
on which registered

Common Stock, $0.10 par value   LH   New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 
 


Item 1.01.

Entry into a Material Definitive Agreement

On June 27, 2025 (the “Closing Date”), Labcorp Holdings Inc. (the “Company”), as parent guarantor, and Laboratory Corporation of America Holdings (“LCAH”), as borrower, entered into a Fourth Amended and Restated Credit Agreement (the “Credit Agreement”) with Bank of America, N.A. (“Bank of America”), as administrative agent, and the other lenders party thereto, which provides for a $1,000,000,000 senior unsecured revolving credit facility (including a $100,000,000 swingline subfacility and a $150,000,000 sublimit for the issuance of letters of credit) (the “Credit Facility”) scheduled to mature on June 27, 2030. The Credit Agreement amends and restates in its entirety the Third Amended and Restated Credit Agreement, dated as of April 30, 2021 (as amended, the “Existing Credit Agreement”), among the Company, LCAH, Bank of America, as administrative agent, and the other lenders party thereto, which provided for a $1,000,000,000 senior unsecured revolving credit facility that was scheduled to mature on April 30, 2026. As of the Closing Date, there were no outstanding borrowings under the Credit Facility.

The Credit Agreement includes the option to increase the amount of the Credit Facility by up to $500,000,000, subject to certain conditions, including obtaining additional commitments from new or existing lenders. Borrowings under the Credit Facility bear interest at a floating rate equal to either (i) a SOFR-based rate plus a margin ranging from 0.805% to 1.300% or (ii) a base rate plus a margin ranging from 0% to 0.300% (in each case, depending on LCAH’s long-term debt ratings). A facility fee ranging from 0.070% to 0.200% (depending on LCAH’s long-term debt ratings) is payable quarterly in arrears on the aggregate amount of commitments in respect of the Credit Facility regardless of usage.

The Credit Agreement contains customary representations and warranties and affirmative and negative covenants, including limitations on the ability of subsidiaries of the Company (other than LCAH) that do not guarantee the Credit Facility to incur debt and limitations on the ability of the Company and its subsidiaries to permit liens, merge or consolidate with others, and dispose of all or substantially all of their consolidated assets, in each case, subject to certain exceptions. In addition, the Credit Agreement contains a financial covenant requiring the Company to maintain, on a consolidated basis as of the last day of each quarterly period, a leverage ratio of not more than 4.0 to 1.0 (which ratio may be increased in connection with a material acquisition to 4.5 to 1.0 for a period of four fiscal quarters (a “Leverage Holiday”) an unlimited number of times during the term of the Credit Agreement, provided that following any Leverage Holiday, LCAH may not make another such election unless and until the leverage ratio shall have been not more than 4.0 to 1.0 for at least two fiscal quarters following the end of the preceding Leverage Holiday). The Credit Agreement also includes events of default customary for facilities of this type. Upon the occurrence of an event of default, among other things, all outstanding loans under the Credit Facility may be accelerated.

The foregoing description does not constitute a complete summary of the terms of the Credit Agreement and is qualified in its entirety by reference to the full text of the Credit Agreement, a copy of which is filed as Exhibit 10.1 to this Form 8-K and incorporated herein by reference.

Some of the financial institutions party to the Existing Credit Agreement and the Credit Agreement and their respective affiliates have performed, and/or may in the future perform, various commercial banking, investment banking and other financial advisory services in the ordinary course of business for the Company and its subsidiaries for which they have received and/or will receive customary fees and commissions.

 

Item 2.03

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

The information set forth in Item 1.01 above is incorporated by reference into this Item 2.03.


Item 9.01.

Financial Statements and Exhibits.

 

(d)

Exhibits

 

Exhibit

  

Exhibit Name

Exhibit 10.1*    Fourth Amended and Restated Credit Agreement, dated as of June 27, 2025, among Labcorp Holdings Inc., Laboratory Corporation of America Holdings, Bank of America, N.A., as administrative agent, and the lenders from time to time party thereto.
Exhibit 104    Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

*

Certain exhibits and schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company hereby undertakes to furnish supplemental copies of any of the omitted exhibits and schedules upon request by the SEC.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

LABCORP HOLDINGS INC.
By:  

/s/ SANDRA D. VAN DER VAART

  Sandra D. van der Vaart
  Executive Vice President, Chief Legal Officer and Corporate Secretary

Date: June 27, 2025

FAQ

What did LH disclose in its June 27 2025 8-K filing?

Labcorp signed a Fourth Amended and Restated Credit Agreement establishing a $1 billion unsecured revolving credit facility maturing on June 27 2030.

How large is Labcorp's new revolving credit facility?

The facility totals $1.0 billion, with an additional $500 million accordion available upon lender commitment.

When does the new credit facility mature?

The maturity date is June 27 2030, extending the prior 2026 expiry by four years.

What interest rates apply to borrowings under the facility?

Borrowings bear either SOFR + 0.805%–1.300% or base rate + 0%–0.300%, tiered to Labcorp’s long-term debt ratings.

Does the credit agreement include financial covenants?

Yes. Labcorp must maintain a consolidated leverage ratio ≤ 4.0×, extendable to 4.5× for four quarters after a material acquisition.

Were any amounts outstanding under the facility at closing?

No. No borrowings were outstanding as of the June 27 2025 closing date.
Labcorp Holdings Inc

NYSE:LH

LH Rankings

LH Latest News

LH Latest SEC Filings

LH Stock Data

21.92B
83.36M
0.34%
96.06%
2.21%
Diagnostics & Research
Services-medical Laboratories
Link
United States
BURLINGTON